Showing results (941-950 of 1,396) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|December 18, 2025
Integrated Genetic Information of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Traits Improves Hepatocellular Carcinoma Risk Stratification and ScreeningMingyi Du, Tianhao Wu, Huangbo Yuan, et al.
JCO Precision Oncology|December 18, 2025
Comprehensive Analysis of the Value of Dynamic Changes in Circulating Tumor DNA in Small Cell Lung CancerAbhishek Ajay, Reza Ferdousi, Peronne L Joseph, et al.
JCO Precision Oncology|October 30, 2025
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of TreatmentAleksandra Markovets, Diana Merino Vega, Chris Abbosh, et al.
JCO Precision Oncology|October 30, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialSarah Scollon, Sharon E Plon, Steven Joffe, et al.
JCO Precision Oncology|October 30, 2025
Clinical Utility of Whole-Genome Sequencing to Aid Histologic Diagnosis and to Direct Personalized Medicine in Salivary Gland CancerMatt Church, George Burghel, Guy Betts, et al.
JCO Precision Oncology|July 1, 2025
Fidelity of Next-Generation Sequencing to Predict Human Epidermal Growth Factor 2 Overexpression Across Solid TumorsMya Tran, Christopher A Fausel, Steven Bray, et al.
JCO Precision Oncology|June 26, 2025
Circulating Tumor DNA as a Biomarker for Disease Surveillance in Anaplastic Thyroid CancerSarah Hamidi, Ramona Dadu, Priyanka C Iyer, et al.
JCO Precision Oncology|July 9, 2025
Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell LymphomaDavidson Zhao, Noémie Lang, Ting Liu, et al.
JCO Precision Oncology|July 9, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair GenesSriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, et al.
JCO Precision Oncology|July 2, 2025
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian CancerYann Christinat, Intidhar Labidi-Galy, Liza Ho, et al.
Pageof 140